Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence

PharmacoEconomics

Volumn 22, Issue 16, 2004, Pages 1047-1059

  Hughes, Dyfrig A ^a   Dubois, Dominique ^b  

^a BANGOR UNIVERSITY   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; OXYBUTYNIN; TOLTERODINE;

ANALYSIS OF VARIANCE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; UNITED KINGDOM; URGE INCONTINENCE;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; COST-BENEFIT ANALYSIS; CRESOLS; DELAYED-ACTION PREPARATIONS; DRUG COSTS; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; MODELS, ECONOMIC; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 10044237662     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422160-00002     Document Type: Review

References (25)

1. Hampel C, Wienhold S, Benken N, et al. Definition of overactive bladder and epidemiology of urinary bladder and epidemiology of urinary incontinence. Urology 1997; 50 Suppl. 6A: 4-14
2. Finkelstein MM, Skelly J, Kaczorowski J, et al. Incontinence Quality of Life Instrument in a survey of primary care physicians [online]. Available from URL http://www.jfpon-line.com.content/2002/11/jfp_1102_0973a.asp [Accessed 2004 Sep 27]. J Fam Pract 2002; 51: 952
3. Finkelstein MM, Skelly J, Kaczorowski J, et al. Incontinence Quality of Life Instrument in a survey of primary care physicians [online]. Available from URL http://www.jfpon-line.com.content/2002/11/jfp_1102_0973a.asp [Accessed 2004 Sep 27]. J Fam Pract 2002; 51: 952
4. Hagglund D, Walker-Engstrom ML, Larsson G, et al. Quality of life and seeking help in women with urinary incontinence. Acta Obstet Gynecol Scand 2001; 80: 1051-5
5. Netten A, Rees T, Harrison G. Unit costs of health and social care 2001. Personal Social Services Research Unit, University of Kent at Canterbury, Kent, UK
6. Department of Health. Prescription cost analysis: England 2001. Department of Health, UK. Available from URL: http://www.doh.gov.uk/stats/ pca2001.htm [Accessed 2003 Jun 20]
7. Bemelmans BL, Kiemeney LA, Debruyne FM. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur Urol 2000; 37: 709-13
8. British National Formulary. Vol. 44. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2002
9. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95: 718-21
10. Harvey M-A, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001; 185: 56-61
11. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001; 76: 358-63
12. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57: 414-21
13. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161: 1809-12
14. Desgagné A, LeLorier J. Incontinence drug utilization patterns in Québec, Canada. Value Health 1999; 2: 452-8
15. Garnett S, Abrams P. The natural history of the overactive bladder and detrosor overactivity: a review of the evidence regarding the long-term outcome of the overactive bladder. J Urol 2003; 169: 843-8
16. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002; 18: 177-84
17. Langman M, Kahler KH, Kong SX, et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 2001; 10: 517-24
18. The Continence Foundation. Making the case for investment in an integrated continence service 2000. The Continence Foundation, London UK. Available from URL: http://www.con-tinence-foundation.org.uk/in-depth/ integrated-continence-ser-vice.php [Accessed 2003 Jun 20]
19. Gupta SK, Sathyan G, Lindemulder EA, et al. Quantitative characterization of the therapeutic index: application of mixed-effects modelling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin Pharmacol Ther 1999; 65: 672-84
20. O'Brien BJ, Goeree R, Bernard L, et al. Cost-effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther 2001; 23: 2038-49
21. Kobelt G, Jönsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: A Markov model. Neurourol Urodyn 1998; 17: 599-611
22. Arikian SR, Casciano J, Doyle JJ, et al. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface 2000; 13: 88-94
23. Roberts RO, Jacobsen SJ, Rhodes T, et al. Urinary incontinence in a community-based cohort: prevalence and healthcare-seeking. J Am Geriatr Soc 1998; 46: 467-72
24. Roe B, Doll H, Wilson K. Help seeking behaviour and health and social services utilisation by people suffering from urinary incontinence. Int J Nur Stud 1999; 36: 245-53
25. Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a systematic review of the literature. Health Econ 2001; 10: 601-5